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http://www.biomedcentral.com/1471-2288/14/3RESEARCH ARTICLE Open AccessDeveloping and validating risk prediction models
in an individual participant data meta-analysis
Ikhlaaq Ahmed1, Thomas PA Debray2, Karel GM Moons2 and Richard D Riley3*Abstract
Background: Risk prediction models estimate the risk of developing future outcomes for individuals based on one or
more underlying characteristics (predictors). We review how researchers develop and validate risk prediction models
within an individual participant data (IPD) meta-analysis, in order to assess the feasibility and conduct of the approach.
Methods: A qualitative review of the aims, methodology, and reporting in 15 articles that developed a risk prediction
model using IPD from multiple studies.
Results: The IPD approach offers many opportunities but methodological challenges exist, including: unavailability of
requested IPD, missing patient data and predictors, and between-study heterogeneity in methods of measurement,
outcome definitions and predictor effects. Most articles develop their model using IPD from all available studies
and perform only an internal validation (on the same set of data). Ten of the 15 articles did not allow for any
study differences in baseline risk (intercepts), potentially limiting their model’s applicability and performance in
some populations. Only two articles used external validation (on different data), including a novel method which
develops the model on all but one of the IPD studies, tests performance in the excluded study, and repeats by
rotating the omitted study.
Conclusions: An IPD meta-analysis offers unique opportunities for risk prediction research. Researchers can make
more of this by allowing separate model intercept terms for each study (population) to improve generalisability, and by
using ‘internal-external cross-validation’ to simultaneously develop and validate their model. Methodological challenges
can be reduced by prospectively planned collaborations that share IPD for risk prediction.
Keywords: Meta-analysis, Prognostic factor, Prognosis, Individual participant (patient) data, Review, ReportingBackground
One of the cornerstones of health and clinical research is
to identify individuals who have a high risk of developing
an adverse outcome over a specific time period, so that
they can be targeted for early preventative strategies
and possibly treatment. For example individuals who are
seemingly healthy but are found to have a high risk of
developing cardiovascular disease could be recommended
to modify their lifestyle and behaviour (e.g. smoking,
exercise, eating habits) to reduce their future risk. They
may also be prioritised for clinical investigation, which
could lead to early diagnosis of an underlying condition
(e.g. diabetes, high blood pressure) and preventative
treatment (e.g. statins or aspirin) to manage it.* Correspondence: r.d.riley@bham.ac.uk
3School of Health and Population Sciences, Public Health Building, University
of Birmingham, Edgbaston, Birmingham B15 2TT, UK
Full list of author information is available at the end of the article
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reproduction in any medium, provided the orFor this purpose of prognostic risk assessments there
is a growing interest in risk prediction modelling, [1-3]
where a statistical model is used to estimate the risk of
future outcomes for individuals based on one or more
underlying characteristics. When considering future out-
comes in patients, a risk prediction model is often referred
to as a prognostic model (typically used for outcome risk for
a defined disease) or more generally a clinical prediction
model (used for both diseased or non-diseased settings)
Similarly the word ‘model’ is often replaced with ‘score’,
‘tool’, ‘index’, or ‘rule’. However, the same principle remains:
to accurately predict the risk of future occurrence of an
outcome in an individual by utilising the values or levels
of multiple individual characteristics. We refer here to
such characteristics simply as predictors, but they are
also termed prognostic factors, risk factors, prognostic
variables, and prognostic markers [4]. They often includeLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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history, but also increasingly include more complex
clinical measures such as biomarkers, relating to a diverse
range of measurable biological (including genomic), patho-
logical, imaging, clinical, and physiological variables.
Diagnostic risk prediction models also exist, where the
risk of already having a disease is calculated; however,
the focus in this article is on predicting the risk of future
outcomes. Unless the outcome prediction relates to the
very near future (e.g. risk of hypocalcaemia within 48
hours after thyroidectomy [5]), single predictors usually
do not provide accurate predictions at the individual-level
[4]. For this reason risk prediction models usually utilise
multiple predictors in combination. For example, in healthy
women the probability of developing breast cancer can be
estimated from the Gail model, which is a risk prediction
model combining information on family history, age, age
at first live birth, age at menarche, breast biopsy number,
and menopause [6,7]. In women with newly diagnosed
breast cancer, a well-known risk prediction model is the
Nottingham Prognostic Index (NPI), [8] which gives a
score that relates to the survival probability and is based
on a combination of tumour grade, number of involved
lymph nodes, and tumour size.
Before evaluation of its impact in daily practice [3,9,10],
risk prediction model research has two main phases:
model development (including internal validation using
the same data or data source) and external validation
(using new data from a different data source) [2,11,12].
Validation requires demonstrating that the model is ac-
curate in the population of individuals for whom it is
intended. It must ascertain the model’s ability to distinguish
between patients with different outcomes (‘discrimination’)
and show the agreement between predicted and observed
risks in groups of individuals with similar risk predictions
(‘calibration’) [1]. Importantly, validation must go beyond
the set of data and individuals that were used to develop
the model, because predictive performance when estimated
on the development data is often optimistic, related to
multiple testing with a limited sample size [1,13,14].
Validation is therefore needed in individuals not used
in the development process and preferably selected
from different settings (external validation) [15].
Unfortunately most publications on risk prediction
models describe model development, and only a small
number report external validation studies [3]. This might
be a key reason why, despite many being developed,
relatively few models are actually being adopted in prac-
tice. The collation and synthesis of individual participant
data (IPD) from multiple studies offers a novel and natural
opportunity to overcome this current lack of validation
[16]. For example, models could be developed using
data from a subset of studies and assessed on data from
the remaining studies [17]. Variation in model accuracyacross studies and its causes could also be explored.
The approach would also unite researchers, increasing
sample sizes and encouraging a consensus towards a
single well developed and validated prognostic model,
rather than a number of competing and non-validated
models for the same clinical question. For example, the
IMPACT (International Mission for Prognosis and Analysis
of Clinical Trials) consortium developed a prediction model
for mortality and unfavourable outcome in traumatic brain
injury by sharing IPD from 11 studies (8509 patients), with
successful external validation using IPD from another large
study (6681 patients) [18].
IPD meta-analysis in this context can also go beyond
using IPD from multiple studies, and more broadly con-
sider synthesising IPD from any relevant clusters in the
wider population of interest. For example, large electronic
databases and registries are increasingly available that
contain routinely collected patient records and risk factor
measurements, which can be linked to health outcomes
using, for example, Health Episode Statistics (HES) linkage.
An example is the THIN database [19], which contains
anonymised patient records and risk factor information
from millions of patients collected from over 500 general
practices in the UK [20], Such databases inevitably contain
clustering of patients, for example within practices, hospitals
and countries, and so an IPD meta-analysis could account
for such clustering, for example by developing a model
using data from a subset of the clusters (e.g. hospitals, prac-
tices), followed by external validation on the remainder.
The aim of this article is to perform a qualitative review
to examine how researchers are developing and validating
risk prediction models when IPD from multiple studies are
sought and then combined for this purpose. The aim is to
identify the current research standards and techniques; the
role of IPD meta-analysis methods toward development
and validation; and the common challenges and meth-
odological problems researchers face. This allows us to
generate a set of recommendations for how research in this
area can be improved, and to flag those methodological
techniques and issues researchers should recognise when
modelling risk prediction using multiple sources of IPD.
Methods
Our review aimed to identify and then evaluate published
articles that developed and/or validated a risk prediction
model using IPD from multiple studies. We now describe
our review methods in detail.
Identifying potentially relevant articles
To identify potentially relevant articles, we used an existing
database of 385 IPD meta-analyses articles that was formed
using a systematic review to identify all IPD meta-analyses
(on any topic) published up to March 2009 [21]. The review
searched Medline, Embase and the Cochrane library using
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an ‘IPD meta-analysis article’ as one seeking, obtaining
and then synthesising raw patient-level data across
multiple studies or multiple collaborating groups. The
articles in the database were published from 1991 to
2009, and it forms the largest collection of IPD meta-
analyses currently available.
Note that our aim was not to review an exhaustive set
of all risk prediction research using IPD from multiple
studies, but rather to identify the main methodological
methods, limitations and challenges therein. Qualitatively
we felt we would achieve saturation with the existing data-
base, and therefore we did not consider it necessary to
update our review with newer articles since 2009.
Inclusion and exclusion criteria
A relevant article was defined as one which sought and
then used IPD from multiple studies to develop and/or
validate a risk prediction model based on one or more
predictors. There were no restrictions on the type of
outcome being predicted or baseline disease/health of
the patients under investigation, or the types of study
(observational studies, randomised trials etc.) being uti-
lised. We use ‘studies’ here loosely to refer to different
research sources, and so it could therefore relate to differ-
ent research centres or collaborating groups. However,
there needed to have been a clear step for obtaining IPD
from the multiple sources. We did not include articles that
used an existing database already containing the multiple
sources (e.g. practices). Though the analysis within such
articles has similar issues, we wanted to focus on the
broader picture of firstly obtaining and then analysing IPD
from the multiple sources (the typical framework for an
IPD meta-analysis).
Similarly ‘model’ is loosely used for any developed
equation, tool, or classification approach that allowed an
individual’s risk to be predicted. Articles that evaluated
one or more factors for their association with outcome
but not their ability to predict individual outcome risk
were excluded; for example prognostic factor, risk factor
and causal factor studies were excluded if they only
considered factors in relation to relative risk (e.g. hazard
ratios, odds ratios) and not also absolute risk (e.g. prob-
ability of death by one year).
IA screened the abstracts and titles of each of the 385
articles and classified them in regards their risk prediction
model status as either ‘yes’, ‘unsure’, or ‘no’. TD then also
independently classified each article as ‘yes’, ‘unsure’ and
‘no’. Finally RR checked all the ‘yes’ and ‘unsure’ articles
and a random 10% of the ‘no’ articles, along with any
‘no’ article containing the words ‘prognostic model’
or ‘prognostic index’ or ‘prediction rule’ or ‘prediction
model’ or ‘risk model’. Any discrepancies between the
three reviewers were resolved through discussion andby obtaining the full papers. Any article deemed ‘yes’ or
‘unsure’ after this screening was then obtained and read
in full by IA and TD, and a final set of relevant articles
decided upon. Any discrepancies were checked by RR
and a final decision was then made.
Data extraction and in-depth evaluation of articles
Each article finally classed as a ‘yes’ was used for in-depth
evaluation. A data extraction form was developed that
included over 70 questions (see Additional file 1). These
questions covered the rationale, conduct, analysis, report-
ing, and feasibility of project developing and/or validating
a risk prediction model using IPD from multiple studies.
A summary of the questions used is as follows:
Background and objectives: e.g. researchers location,
year of publication, research aim, the baseline condition
of patients, and the outcome to be predicted.
Identifying IPD studies: e.g. how they relevant studies
for inclusion were identified, what types of studies were
included, whether the targeted number of patients or
studies was explained or justified statistically, etc.
Obtaining IPD: e.g. how authors asked for and obtained
IPD, what proportion of IPD requested was actually
obtained, whether study quality was considered, etc
Missing data: e.g. if there were any missing data, either
at the patient-level or study-level, and if so how it
was handled?
Model development: e.g. the statistical methods used to
develop the risk prediction model, how data coming
from multiple studies was handled, whether
heterogeneity between studies was considered, how
continuous predictors were handled, and whether the
final model was fully presented.
Model validation: e.g. the statistical methods and
criteria used for (internally or externally) validating the
prediction model, how multiple studies were handled in
this process, etc.
Potential for bias: e.g. potential impact of studies not
willing/able to provide IPD on the estimates of model
performance (e.g. in terms of calibration and
discrimination) for the intended model’s use and
target population.
Conclusions: e.g. the key conclusions and recommendations,
and the limitations and problems discussed.
IA read each article in full and extracted information
that answered these 77 questions, and then TD also in-
dependently answered these questions for each article.
Any discrepancies in responses were resolved with RR.
Results
The classification process identified 15 relevant articles
each of which used IPD from multiple studies to develop
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more predictors) for outcome risk [5,18,23-35]. They were
published between 1994 and 2008, and their background
and aims are summarised in Table 1. All 15 of these arti-
cles developed a model, and 11 also undertook some form
of validation of their model [5,18,23,26,27,29-31,33-35].
By evaluating these 15 articles the team considered that
qualitative saturation had been achieved. We now provide
a qualitative summary of the key findings.
Background and objectives
The central location of the 15 IPD projects (where the first
author was located) included the USA and Australasia, but
most were from Europe (11), especially The Netherlands
(4) and the UK (3). Just three of the 15 articles referred to a
protocol for their IPD project, and only six mentioned
obtaining ethics approval.
Thirteen articles considered patients who were diseased
at baseline; for example Sylvester et al. [33] estimate a
superficial bladder cancer patient’s probability of recur-
rence and progression at one and five years. The other
two articles considered patients who were healthy at
baseline (Table 1); for example Fowkes et al. [25] predict
the risk total and cardiovascular mortality in healthy in-
dividuals. The diseases considered at baseline included
pancreatic cancer, chronic hepatitis C, bladder cancer
and post-myocardial infarction among others (Table 1).
The outcomes being predicted were either general (e.g.
mortality) or disease-specific (e.g. development of radi-
ation myelopathy, fatal coronary heart disease within 10
years, postoperative symptomatic hypocalcemia) (Table 1).
Thirteen of the 15 articles primarily described a mul-
tivariable risk prediction model; that is, a model which
included multiple predictors. The other two articles
examined the predictive accuracy of a single predictor.
Noordzij et al. [5] assessed the accuracy of % change in
parathyroid hormone (PTH) levels from pre- to post-
thyroidectomy for predicting hypocalcemia within 48
hours, whilst Raboud et al. [30] consider the accuracy
of plasma viral load (pVL) to predict virologic outcome
at week 52 in patients receiving antiretroviral therapy.
Obtaining IPD from multiple studies
Across the 15 articles, there were two competing ap-
proaches to initiating risk prediction model research using
IPD from multiple studies: either perform a (systematic)
literature review and seek IPD from relevant studies identi-
fied (seven articles) [5,25-28,31,34], or set-up a collaborative
group of selected researchers who agree to share their IPD
(seven articles) [18,23,24,29,30,32,33]. In one article it was
unclear how IPD studies were identified [35].
Of the seven articles using a literature review, only three
described how they contacted study authors to obtain
their IPD and this included e-mail, postal mail, andtelephone. Six of the seven articles did not obtain IPD
for all studies desired, and only three of these six articles
explained why they could not obtain all IPD desired.
For example, Heffner et al. [26] stated that some IPD
requested was no longer available or had not been
saved in some studies. The % of IPD obtained in the
seven articles ranged from 50% to 100% (Figure 1), with
the median 60%.
Details of IPD obtained
The types of studies providing IPD were stated by 12 of
the 15 articles. Seven articles used IPD from only rando-
mised controlled trials (RCTs), four used only observa-
tional studies, and the remainder (Steyerberg et al. [18])
used from both RCTs and observational studies. In the
eight articles that used RCTs, five used the data from all
treatment groups, two just used the placebo group, and
Steyerberg et al. used all the data in their primary analysis
but just the placebo group for their secondary analysis.
A summary of the sample population (i.e. mean and
summary patients characteristics) were given for each IPD
study separately in eight of the 15 articles (e.g. Pagliaro
et al. [29]), whilst five articles gave a summary just across
the overall IPD, and two articles did not give this informa-
tion. Only one of the 15 articles mentioned performing an
assessment of quality for studies considered, which was
Rovers et al. [31], although it was not clear if this had
implications for the IPD they ultimately analysed.
Fourteen of the 15 articles gave the number of patients
within each of the IPD studies, and the remaining article
(Rovers et al. [31]) gave just the overall number of patients
across all studies. Seven of the 15 articles gave the total
number of events for each predicted outcome within each
of the IPD studies, (e.g. Yap et al. [35]), whilst six just gave
the overall number of events across all studies and two
articles did not give this information at all (e.g. Raboud
et al. [30]). Only four of the 15 articles gave the number
of events per candidate predictor to be considered for
inclusion in the model. Two of these gave this information
within each IPD study separately, and the other two
provided this information just across all studies. Nine of the
15 articles reported the number of events per candidate
predictor in each IPD study, whilst three others gave
this in terms of the overall IPD across all studies, and
the remaining three did not report this information.
Missing data
Eight of the 15 articles mentioned having missing patient
data for some variables. For example Noordzij et al. [5]
state that only six of the nine studies that supplied IPD
obtained preoperative PTH values, and Fowkes et al.
[25] that say 3.9% of the overall values were missing in
their data. Eight of the 15 articles also reported having
missing whole variables in some of their IPD studies; for
Table 1 Summary of the 15 articles included in the review
First author
and year of
publication
First author
location
Research aims Baseline condition
of participants
Main outcome(s) of
interest for prediction
Approach to identify
relevant studies
Number of studies
providing IPD
(Number requested)
Pagliaro (1994) [29] Italy To identify predictors of short-term and
sustained Alanine transaminase (ALT)
normalization after interferon treatment
in adult patients with hepatitis C
Adult patients with transfusion-
related or community-acquired
Short term and sustained
response (ALT normalization)
Collaborative group 2 (NA)
Heffner (2000) [26] USA To determine the predictive accuracy of
pH for identifying patients with malignant
pleural effusions who will fail pleurodesis
Patients with malignant
pleural effusions
Failure of pleurodesis Literature review 6 (12)
Raboud (2000) [30] Canada To determine the ability of intermediate
plasma viral load (pVL) measurements to
predict virologic outcome at 52 weeks
of follow-up in clinical trials of
antiretroviral therapy
Patients within a particular range
of CD4 cell counts, naive to
antiretroviral therapy and not
been previously diagnosed
with AIDS
Virologic outcome at 52
weeks of follow-up
Collaborative group 3 (NA)
Terwee (2000) [34] Netherlands To develop a prognostic tool for patients
with unresectable pancreatic cancer to
distinguish between low or high probabilities
of survival 3 to 9 months after diagnosis.
Patients diagnosed with
pancreatic cancer
Overall survival Literature review 8 (15)
Chau (2004) [24] United Kingdom To identify baseline patient- or tumour-
related prognostic factors; and to assess
whether pre-treatment quality of life
predicts survival in patients with locally
advanced or metastatic esophago-
gastric cancer.
Patients with histologically confirmed
inoperable adenocarcinoma, squamous
cell carcinoma, or undifferentiated
carcinoma of the oesophagus,
esophago-gastric junction, or stomach
Overall survival Collaborative group 3 (NA)
Horn (2005) [27] Netherlands Investigate if transcranial doppler
monitoring for micro embolic signals,
directly after carotid endarterectomy
(CEA) identifies patients at risk of
developing ischaemic complications.
Carotid endarterectomy patients Cerebral ischaemic
complications, defined as
new neurological deficits
within 1st week after CEA
Literature review 7 (10)
Nieder (2005) [28] Germany Identifying the predictive value of
biologically effective dose as function
of the risk of myelopathy
Patients with spinal cord retreatment Development of radiation
myelopathy
Literature review 8 (8)
Asia pacific group
(2006) [23]
Australia To investigate the generalisability of
current definitions of the metabolic
syndrome in Asia-Pacific populations,
and assess the prognostic value of
metabolic risk factors to discriminate
fatal coronary heart disease (CHD) risk
Healthy patients aged 30–75 Fatal CHD within 10 years Collaborative group 26 (NA)
Sylvester (2006) [33] Belgium To predict a superficial bladder cancer
patient’s probability of recurrence and
progression at one and five years
Stage Ta, T1, and Tis bladder
cancer patients who have
undergone transurethral resection
Time to first recurrence
(disease-free interval) and
time to progression to
muscle invasive disease
Collaborative group 7 (NA)
Noordzij (2007) [5] USA Early prediction of hypocalcaemia
after thyroidectomy using
parathyroid hormone
Patients undergoing thyroidectomy Postoperative symptomatic
hypocalcaemia
Literature review 9 (15)
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Table 1 Summary of the 15 articles included in the review (Continued)
Rovers (2007) [31] Netherlands To determine the predictors of a
prolonged course for children
with acute otitis media (AOM) to
discriminate between children
with and without poor outcomes
Children with AOM A prolonged course of
AOM (pain and/or fever
at 3 to 7 days)
Literature review 6 (10)
Schaich (2007) [32] Germany To identify prognostic indicators in
acute myeloid leukaemia (AML) to
provide a new prognostic model for
risk stratification of AML patients
AML patients Overall survival and
relapse-free survival
Collaborative group 8 (NA)
Fowkes (2008) [25] United Kingdom To determine if the ankle brachial index
provides information on the risk of
cardiovascular events and mortality
independently of the Framingham
risk score and can improve
risk prediction
Participants of any age and
sex derived from a general
population
Total and cardiovascular
mortality
Literature review 16 (20)
Steyerberg
(2008) [18]
Netherlands To develop prediction model for
predicting unfavourable outcome
according to the glasgow outcome
scale (GOS) at 6 months after
traumatic brain injury (TBI)
Patients with moderate or severe
TBI (with GOS > = 12)
6-months mortality and
unfavourable outcomes
defined by 6 months GOS
Collaborative group 11 (NA)
Yap (2008) [35] United Kingdom To design a prognostic indicator
using demographic information to
select patients at risk of dying after
myocardial infarction (MI)
Patients at day 45 post-MI up
to 2 years
All-cause, arrhythmic and
non-arrhythmic cardiac
mortality within 2 years
Not stated 4 (unknown)
NA not applicable.
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Figure 1 Number of studies for which IPD was requested and obtained in the seven articles using a literature review to identify
relevant studies to seek IPD from.
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activity was not recorded in two trials”.
If an article reported that missing patient data occurred
for a variable, then generally the article either stated
that patients with missing data were excluded from the
analysis (e.g. Heffner et al. [26]), or they used a (multiple)
imputation approach (e.g. Steyerberg et al. [18] and Rovers
et al. [31]). Additionally three of the 15 articles entirely
deleted some studies due to absence of a particular pre-
dictor or even outcome of interest. For example, Terwee
et al. [34] excluded three of their eight studies, stating:
“one study was excluded because we could not distinguish
between patients with tumours of the pancreatic head and
tumours of the pancreatic body or tail, and two others were
excluded because information on metastases was lacking
or incomplete”.Model development
We now summarise the statistical analysis methods used
for model development. Our main focus here is on how
IPD from multiple studies were handled.Analysis method
The number of patients and events used from each study
separately towards the prediction model development was
given for 10 of the 15 articles, (e.g. Yap et al. [35]), with
the remainder focusing on the numbers overall.
The two articles that considered a single predictor
examined predictive performance by calculating ROC
curves from the data. In the 13 articles developing a
multivariate model, six used Cox regression (e.g. Terwee
et al. [34]), five used logistic regression (e.g. Heffner et al.
[26]), and Patel et al. [23] used both Cox and logistic
regression. Nieder et al. [28] did not state the analysis
method used.All 15 articles used the IPD from multiple studies to
develop their models (i.e. none used just one study for
development). Ten of the 15 articles pooled all the IPD
available into one big dataset and analysed it ignoring
clustering of patients within studies or collaborative groups
(this is often referred to as a ‘one-stage meta-analysis
ignoring clustering’ [36]), mostly without explaining why
clustering was ignored. A notable exception is Terwee
et al. [34], who justify their approach by examining
whether stratification by study was necessary, stating:
“The homogeneity assumption was checked by including
treatment as a dummy-coded variable into both models
(stratification per study). Initially we found a significant
survival benefit for patients treated by surgical bypass
procedures compared with endoscopic stents. However,
this effect disappeared after adjustment for Karnofsky’s
index (a measure of functional status) in the study in which
this variable was available, which legitimises pooling”.
Three of the remaining five articles developed their
model via a ‘one-step meta-analysis analysis accounting
for clustering’, where the IPD from all studies/collabora-
tive groups are analysed together but with clustering by
study/group accounted for (e.g. using a dummy variable
for study, such as Steyerberg et al. [18]). In another article,
Fowkes et al. [25] developed their model using a two-
step meta-analysis approach, where the IPD are first
analysed separately in each study, and then their model
estimates are pooled together in second-step. Specific-
ally, they estimate a Kaplan Meier curve for each study,
and then do a random effects meta-analysis of the
study survival percentages estimated at different time-
points (to give an average % survival predicted across
studies). In the remaining article, Schaich et al. [32] use
a hierarchical cluster approach, but it is not clear
whether this cluster approach specifically included cluster-
ing by study.
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Twelve articles did not consider between-study het-
erogeneity in the predictive effect of their included
predictors. Of the three articles that did consider such
heterogeneity, Steyerberg et al. [18] state: “Similarly,
study-specific effects were assessed with interaction
terms between study and each predictor. Interaction
terms between predictors were examined with likelihood
ratio tests, but none was of sufficient relevance to extend
the models beyond the main effects for each predictor”.
Rovers et al. [31] assessed heterogeneity through the
I2 statistic and state: “To determine whether pooling
was justified, heterogeneity between studies was assessed
with the I2 statistic. Because the I2 value was 25%,
pooling was performed”. Fowkes et al. [25] tested for
heterogeneity (using Chi-square test and I2), for one of
their predictors; they then applied random effects in
their analysis which, although not explicitly stated, is
likely due to heterogeneity being detected.Handling of continuous predictors
Continuous predictors were analysed on a continuous
scale in four of the 15 articles. For example, Steyerberg
et al. [18] state: “For the continuous predictor’s age, glucose,
and Hb, a linear relationship with outcome was found to
be a good approximation after assessment of non-linearity
using restricted cubic splines”. The remaining 11 articles
either categorized or dichotomized the continuous pre-
dictors of interest. For example, Heffner et al. [26] state
that “continuous variables were entered as dichotomous
indicator variables with test thresholds determined by
ROC analysis”, and Chau et al. [24] state: “Laboratory
variables were initially coded as continuous variables
and subsequently dichotomised with the cut-off points
chosen at the median value of each variable”.Need for standardisation
Three of the 15 articles mentioned the need to stand-
ardise the coding of predictors and outcome defini-
tions across studies. For example, Terwee et al. [34]
state “To standardise definitions among the different
studies, the presence of metastases and of pain and
weight loss at diagnosis were classified as ‘present’ or
‘absent’”, whilst Noordzij et al. [5] handle different
methods of measuring PTH values by analysing %
change in PTH from baseline, rather than analysing
PTH on its original scale. In order to use and compare
candidate predictors factors measured on different
continuous scales, Steyerberg et al. [18] standardised the
reporting of odds ratios so that they corresponded to a
change from the 25th percentile to the 75th percentile of
the predictor distribution.Strategy for inclusion of predictors
Of those 13 articles developing a multivariable model with
multiple candidate predictors for inclusion, the most
common approach was to use p-values to decide which
factors were included. For example Heffner et al. [26]
state: “Variables that were found by univariate analysis
with p < 0.10 were entered in the model. Variables were
removed from the model if their p values were > 0.05.
This process identified 4 clinical variables. The four
clinical variables were entered into the logistic regression,
and only pH was identified as an independent predictor”.
Four of the articles used a selection procedure such as
forwards, backwards or stepwise selection.Reporting of developed model
Of those 13 articles developing a multivariable model,
the developed model was poorly reported on its original
scale. For example, of the six articles that used a Cox
model, only Terwee et al. [34] gave the beta (log hazard
ratio) estimates for each included predictor, with others
mainly reporting hazard ratios for each variable. None of
those six articles that used logistic regression reported
the alpha term (baseline risk) for their full model, and
only two reported the beta (log odds ratio) estimates for
each predictor, with the remaining four articles presenting
odds ratios. However, Steyerberg et al. [18] do present a
simplified version of their logistic regression model (based
on a simple score chart), in which they do present the
alpha and beta terms.Model validation
We now consider if and how articles validated their
developed model. We refer to ‘internal validation’ when
the same data are used to validate the model as to develop
it, and ‘external validation’ when the data are used to
validate the model are different than the data used for
development. We also refer to ‘internal-external cross-
validation’ [16,17], which is a multiple validation approach
that accounts for multiple studies by rotating which are
used toward model development and validation. Briefly,
this technique excludes one of the IPD studies from the
available set, and the remainder are used to develop the
prediction model; the excluded study is then used to valid-
ate the model externally. This process is repeated for each
study omitted in turn, and this allows the consistency of
the developed model and its performance to be examined
on multiple occasions. If the model performs consistently
well in all external datasets, then all IPD studies can be
used for model development. If, however, it performs
poorly in some external datasets, this may flag up hetero-
geneous studies (populations) for which the model does
not generalise to and thus warrant exclusion.
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Four articles did not use any validation approach. Nine
of the other 11 articles performed internal validation,
using the same IPD as that used to develop the model.
For example, Noordzij et al. [5] examined the accuracy
of PTH by calculating the ROC curve in all of the IPD
available. However, a few of these nine also recognised
that model accuracy may be over optimistic in the
development data, and so tried to correct for this. For
example, Paglioro et al. [29] took a random test set of
100 patients from their development data of 261 patients;
they show that the area under the ROC curve was slightly
lower in the test data than than the full original data
(e.g. their model 1: AUC =0.728 (n = 261) vs. AUC= 0.659
(n = 100)). Sylvester et al. [33] performed bootstrap resam-
pling of all the IPD available and then examined model
performance in these samples, leading to a bias-corrected
C-statistic.
Steyerberg et al. [18] used both external validation and
internal-external cross-validation. For external validation
they use IPD from a trial different than that used to
develop the model, but note problems with missing
variables: “We aimed to validate all models externally
using data from selected patients in the CRASH trial.
However, lab values were not recorded in this trial, nor
were hypoxia, hypotension, and EDH. We therefore vali-
dated the core model, and a variant of the extended model,
in which only the Marshall CT classification and presence
of tSAH were added to the core model (i.e., the core +
CT model)”. Interestingly, their developed model was
stratified by study and so had multiple intercepts to
choose from. However, in their validation they appear to
choose one intercept related to a single trial as “it repre-
sented typical proportions of mortality (278/1,118, 25%)
and unfavourable outcome (456/1,118, 41%)”.
When performing internal-external validation, Steyerberg
et al. [18] state: “AUC was calculated in a cross-validation
procedure, where each study was omitted in turn. Results
were pooled over the ten imputed datasets for eight studies
with sufficient numbers for reliable validation (n > 500)”.
Yap et al. [35] also used internal-external cross-validation,
stating: “The use of several different studies provided an
opportunity to validate the general method using data
drawn from a different patient population using an
internal–external cross-validation system proposed by
Royston et al. that leave-one-out cross-validation on a
cohort basis. We therefore, sequentially designated one
of the trials as a test study. The remaining studies acted
as a training data set, which was used to generate the
risk scores”.
Reporting of validation criteria
Validation criteria focused on discrimination, calibration,
and goodness of fit. Of the 11 articles that examinedvalidation, 10 gave discrimination statistics such as sensitiv-
ity, specificity, AUC and C-statistic. Three articles reported
calibration statistics such as the Hosmer-Lemeshow
goodness-of-fit test. Eight provided figures to show
model discrimination, accuracy, or calibration. The most
common figure was an ROC curve, but Steyerberg et al.
[18] present calibration figures depicting predicted and
actual outcome probabilities, and Yap et al. [35] pre-
sented survival curves for each split-validation sample,
to illustrate the consistency of the model in identifying
risk categories.
Dealing with those studies not willing/able to provide
their IPD
In six of the seven literature review articles (Figure 1),
IPD had not been obtained for all desired studies, but
only three of these discussed whether this was a limitation
of their project. For example, Horn et al. [27] note: “We
may not have identified all centres, which monitor MES
after carotid surgery: it is likely that small series of
patients remain unpublished and have therefore escaped
our attention”. None of the six articles gave the number
of patients and events in the missing IPD studies, and
only one article discussed the qualitative or quantitative
differences between those studies providing IPD and
those studies not able to.
Conclusions and limitations
The developed risk prediction models had large potential
for use in clinical practice, according to the discussion of
the 15 articles, highlights the value of collecting IPD from
multiple studies. For example, Noordzij et al. [5] state “PTH
assay, when checked 1 to 6 hours after thyroidectomy,
has excellent accuracy in determining which patients
will become symptomatically hypocalcemic”, whilst Yap
et al. [35] state “our study suggests that in post-MI patients,
pre-selected using LVEF or frequent ventricular premature
beats, the additional use of a simple prognostic indicator
based on demographic and baseline information was able
to segregate patients that were at high risk of dying, for 3
different modes of mortality”.
However, numerous limitations and problems of the
IPD projects were also noted in the articles’ discus-
sion section, especially dealing with missing data and
between-study heterogeneity in definitions, time-periods,
treatments used, study quality, and different methods
of measurement. The key methodological problems are
summarised in Table 2.
Discussion
Risk prediction models have the potential to inform
strategies for disease prevention, early diagnosis, patient
counselling and therapeutic care [1]. As for all clinical
practice, their use should be evidence-based. In particular,
Table 2 Methodological challenges when developing and validating a risk prediction model using IPD from multiple
studies as identified from those 15 articles in our review (written below in a framework similar to recommendations
by Abo-Zaid et al. [37] for prognostic factors)
Methodological issue Challenge
Identifying relevant studies • Unavailability of IPD in some studies
Issues within studies • How to assess quality of studies available
• Inability of IPD to overcome deficiencies of original studies, such as missing participant
data or of being low methodological quality.
Heterogeneity across studies • Dealing with different definitions of disease or outcome
• Dealing with different (or out-dated) treatment strategies, especially when a mixture of
older and newer studies are combined
Statistical issues for meta-analysis • Dealing with a mixture of IPD from retrospective and prospective studies
• Missing data, including: missing predictor values and missing outcome data for some
participants within a study, and completely unavailable predictors in some studies
• Difficulty in using a continuous scale for continuous factors in meta-analysis when some
IPD studies give values on a continuous scale and others do not
• Dealing with IPD from trials where both control and treatment groups are available
Assessment of potential biases • How to assess the impact of excluded studies who did not provide IPD
Model development • Accounting for clustering of patients within different IPD studies
• Allowing for heterogeneity in baseline risk (intercept term) across studies
• Allowing for heterogeneity in predictor effects across studies
Model validation • Lack of external validation if all studies used for model development
• Sample size required to implement the internal-external approach (i.e. sample size of
studies to be excluded, and also the total number of IPD studies needed)
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and applicable to the intended populations of individuals
[3]. This ideally requires the model to be successfully
validated in multiple datasets external to the model
development phase. This can often take many years to
achieve. However, with increasing access to the IPD
from existing studies or large databases, there is a
growing opportunity to both develop and validate risk
prediction models simultaneously, within an IPD meta-
analysis framework [16].
In this article we have reviewed 15 articles that each
used IPD from multiple studies to develop and potentially
validate a risk prediction model for the development of
future outcomes. This has allowed us to identify good
practice, useful statistical methods, methodological chal-
lenges (Table 2), and some limitations in current reporting
and methodology to be addressed (Table 3). We recognise
that our review also has limitations. Firstly, it only covers
articles published up to 2009, which was a restriction on
the database we used; however we feel that our findings
are unlikely to be different if the review were updated,
and that qualitative saturation of issues and concepts
had been achieved with our sample. Secondly, we focused
on articles that utilise IPD obtained from multiple studies
(or sources), and did not consider articles which used a
single database containing clustering (e.g. by practice);
such articles raise similar issues for the analysis, but wewanted to focus on the typical IPD meta-analysis scenario
where IPD studies are obtained and then synthesised.
Thirdly, by evaluating published articles we recognise our
findings are clearly dependent on the reporting standards
within the articles; thus any apparent research deficiencies
or methodological gaps may just reflect poor reporting
standards. Nevertheless, we believe our review and its
findings will help inform those who wish to develop or
validate a model using IPD multiple studies in the future.
In particular, our work allows us to provide some key
recommendations for improving the design, conduct and
reporting of future research this field (Table 3), which
echo those for IPD meta-analysis of prognostic factor [37]
and modelling [16] studies, and concur with previous
[38,39] and ongoing [40] work toward improved reporting
of risk prediction model articles in general. For brevity we
do not discuss all these in detail now, but rather focus on
the two most important recommendations in detail.
Recommendation 1: allow for different baseline risks in
each of the IPD studies
In our review, 10 of the 15 articles did not account for
clustering of patients within different IPD studies and
therefore their developed prediction model did not allow
for any study differences in baseline risk. Although such
models can still perform adequately on average (that is,
across all studies combined), when applied in practice to
Table 3 Recommendations for improved research when developing and validating risk prediction models from
multiple studies
Area for improvement Recommendations
Rationale and initiation • Produce a protocol for the project, detailing rationale, conduct and statistical analysis and reference this
Obtaining IPD • Report how the primary study authors were approached for their IPD
• Report strategy used to identify relevant studies, e.g. literature review/collaborative group
• If literature review performed, then report search strategy, including keywords and databases used
• Provide a flowchart showing the search strategy, classification of identified articles, and retrieval of IPD
from relevant studies
• Report any prior sample size considerations used, such as the number of IPD studies deemed necessary and
the number of patients and events required. If no sample size requirements were considered, report this also
Details of IPD • Report the number of patients and events for each study used in model development and/or validation
• Report the missing data for each study (e.g. whether predictors were missing entirely, or how many patients
had predictor values missing), and whether some patients or studies were entirely excluded for this reason
• Detail the reasons why IPD was unavailable in some desired studies (if applicable), and report the number
of patients and events from these studies
• If any studies were excluded after IPD was obtained, provide the number of studies excluded and explain
why they were removed (e.g. missing predictors, different outcome definition, different methods
of measurement)
• Compare and report the quality of studies for which IPD was obtained
Statistical methods for model
development
• Account for clustering of patients within studies, for example by allowing for a separate intercept per study
• Report the selection criteria and procedure used to decide which predictors are included in the final model
• Assess and report any between study heterogeneity in the effects of included predictors
• If large heterogeneity does exist in particular predictors, then try to reduce it by including more predictors
or simply focus on including homogenous or weakly heterogeneous factors
• Where possible model continuous predictors on their continuous scale, unless it is important to categorise
with good clinical or statistical reason
• Report the final developed model in original format with alpha (baseline risk) and beta estimates, so that
others can ascertain how apply the model in practice
• Detail how missing patient-level data and missing study-level factors were dealt with in the analysis
Model validation
and implementation
• Validate the model that has been developed using internal-external cross-validation; we tentatively suggest
at least 4 studies are required for this approach however.
• Explain the choice of intercept (baseline hazard) to be used when implementing the model in the
excluded study
• Report validation statistics for each study excluded in the internal-external cross validation method
• Report clearly whether there is evidence the model performs consistently well during the
internal-external validation
• If it performs consistently well, clearly report the final overall prediction model to be used in practice,
and emphasise again how the intercept should be chosen upon application
- If it does not perform consistently well, clearly flag those populations for which the model cannot
be applied and draw attention to the model’s lack of generalisability
Impact of missing IPD studies • If possible, compare the populations of those studies not providing IPD to those studies providing IPD,
to be able to understand whether the developed model may need further generalisation in such
populations in the future
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teriorate considerably if the population’s baseline risk is
very different from the average estimated during model
development. In other words, the developed model may
require re-calibration in particular populations. Statistically
it is also know than omission of an important predictor
(i.e. study) can lead to biased effect estimates and reduced
power [36]. To address this, Debray et al. [16] recommendthat the prediction model should be developed with a
separate intercept (baseline risk) per study, and then
the model’s performance can be examined using internal-
external validation alongside a strategy for choosing the
intercept upon application to the excluded study. Such
strategies may include using external knowledge of the
intercept in the excluded study population; using the
intercept as estimated from the IPD from the excluded
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used in the model development that contains a similar
population to the excluded study. The latter strategy is
recommended within Steyerberg et al. [18], where they
propose others apply their model using the intercept
for one particular trial in their analysis, as this trial is
reflective of the population intended.
Where the intercept can be well-matched to the excluded
study, Debray et al. [16] show that their framework allows
an IPD meta-analysis to produce a single, integrated pre-
diction model from that can be implemented in practice
and has improved model performance and generalisability.
This echoes other recommendations to account for
clustering in an IPD meta-analysis [36]. For survival data,
this means that the baseline hazard should be modelled
during model development and so researchers should
move away from using Cox regression (a common ap-
proach in the articles in our review, but one which does
not estimate the baseline hazard) and rather use other
approaches such as flexible parametric methods, like
the Royston-Parmar model that estimates the baseline
hazard using restricted cubic splines [41,42].
A similar recommendation is for researchers to examine
between-study heterogeneity in predictor effects. This
is currently rarely done. Debray et al. [16] show that a
model’s performance is likely to be more consistent if
there is little or no heterogeneity in the effect of the
predictors included. Researchers should examine hetero-
geneity and prioritise inclusion of homogeneous and only
weakly heterogeneous predictors, or attempt to include
interaction terms or additional predictors that reduce
heterogeneity in others. The choice of predictors and their
specification in the model (e.g. with transformation,
and/or with linear or non-linear trends) is a complex
issue, and statistical software procedures to integrate
such decisions in the context of an IPD meta-analysis
would be very helpful.
Recommendation 2: implement a framework that uses
internal-external cross-validation
A major finding from our review is that, despite the
availability of multiple studies, most researchers develop
their model by using the IPD from all available studies,
and so then perform an internal validation (on the same
set of data) rather than an external validation (on different
data). Only two of the 15 articles used a form of external
validation, and so most models require further validation
in order to investigate their true performance. One
plausible reason why researchers choose not to use
IPD for external validation is that they want to maximise
the data available for model development; this is under-
standable, especially when faced with a large set of can-
didate predictors and possible non-linear relationships.
Furthermore, even if researchers do decide to hold-back some IPD for external validation, it is not easy to
decide how much IPD (and how many studies) should
be removed.
For these reasons, the internal-external cross-validation
approach is highly appealing [16,17], yet seemingly under-
utilised. It wasused by Steyerberg et al. [18] and Yap et al.
[35] in the articles we reviewed up to 2009. We also
performed a citation search of the Royston et al. [17]
article that proposed the method. By the end of 2012
(based on abstracts of citations identified) there were still
only nine citing articles (including the aforementioned
Yap and Steyerberg) that developed a prediction model.
The internal-external cross-validation approach involves
removing just one study from the development phase of
the model, fitting the model on the remaining IPD, and
then testing performance in the excluded study. This
framework is then repeated by rotating the omitted study
and assessing the validation in all the possible scenarios.
Model estimates are therefore always based on the major-
ity of IPD, and its model fit and predictive ability can
be appraised across all the studies simultaneously. Where
performance is consistently adequate across all combina-
tions of the omitted study, a final step can be to utilise
the IPD from all studies to produce the final specification
of the model. In situations where model fit appears inad-
equate in some excluded studies, then this identifies a lack
of generalisability and highlights populations (studies)
for which the model is not currently suitable for. It also
signals the need to improve the current model specifica-
tion, for example by including additional predictors with
homogenous effects across studies.
Royston et al. [17] originally proposed the internal-
external validation approach for survival data, within
a framework to construct and validate a prognostic
survival model from an IPD meta-analysis [12]. This
framework allowed them to evaluate whether derived
models have good prognostic separation in independent
studies and whether the baseline survival distribution is
heterogeneous across studies. Afterwards, a single final
model was derived from all available IPD using flexible
parametric proportional hazards (PH) modelling tech-
niques. This article has only been cited 26 times between
2004-2012, again showing the general lack of uptake of
this method. We hope this will change as researchers
become more aware of its usefulness. Debray et al. [16]
recently extended the methodological framework to
binary outcomes where logistic regression models are
used to develop the risk prediction model.
How many IPD studies are needed and should all
available IPD be used?
We recognise that implementing these two recommen-
dations may be difficult given only a few IPD studies
and/or when the number of patients per study is small.
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on the necessary sample size to implement the internal-
external approach, in terms of both the total number of
IPD studies needed (Debray et al. [16] tentatively suggest
at least four or five) and the sample size (number of
patients and events) within those studies that are excluded
from model development. With small sample sizes,
internal-external validation may not be plausible; for
example, Nieder et al. [28] only obtained IPD for 40
patients in total across eight case series reports. How-
ever, such small sample sizes are perhaps less likely to
be an issue when using data from trials, prospectively
planned cohort studies, or large electronic databases.
Given a set of available IPD studies, researchers should
begin by identifying those that are relevant and most
reliable for the clinical question at hand. It may be entirely
sensible to exclude some available IPD for a variety of
reasons framework [16]. For example, researchers should
evaluate the outcome definitions used in each study, and
exclude studies that are not consistent (and cannot be
made consistent) with others. They should also check
whether important predictors are recorded in each
study, and evaluate the amount of missing data for
available predictors; though multiple imputation can
limit these issues, studies with multiple missing predictors
or large proportions of missing values might be best
excluded for robustness (unless imputation assumptions
can be justified). Studies may also be removed if they have
crucial differences in such as: the method of measuring an
important predictor; the treatment and healthcare patients
received during follow-up; and the start-point (baseline)
entry of patients to the study (e.g. one year after treatment,
rather than at the time of diagnosis). If ignored, such
differences might limit clinical interpretability of any
model produced and reduce its performance. The number
of studies excluded, and the decisions that lead to this,
should always be transparently reported upon publication
(Table 3).
A further issue arises when IPD are not available for
all desired studies. This raises the threat of availability bias,
where studies not providing their IPD are potentially dif-
ferent to those that do provide IPD [43]. For a traditional
meta-analysis of treatment effects, this can cause bias
in the summary meta-analysis result [43]. In the context
of risk prediction models, it might cause the developed
model to be unreliable in those populations (studies)
which did not provide their IPD, and therefore reduce
its usefulness in practice until further validation studies
can be undertaken in these populations.
Finally, an issue rarely considered is whether ethical
approval is required to collate IPD from multiple studies.
Only six of the 15 articles mentioned that had ethical
approval. One might argue that ethical approval is not
required when IPD is being used in accordance with theoriginal objectives of the studies involved (that is, to
understand and improve the prognosis of patients). We
hope that most ethics committees will support this view,
but it should at least be checked that the studies providing
IPD actually had ethics approval themselves.
Conclusions
It is paramount to consider statistical and methodological
issues when planning to develop and/or validate a risk
prediction model from multiple datasets, in order to avoid
poorly generalisable and poorly performing models. Our
review highlights that the IPD meta-analysis approach is
highly appealing, as it allows the use of internal-external
cross validation to develop a model and simultaneously
evaluate its performance across multiple populations.
However, researchers are faced with numerous challenges
when the IPD is collated, in particular missing data and
heterogeneity in study quality and methods of measure-
ment. Perhaps an ideal way forward is a prospective
IPD meta-analysis, where researchers agree at their study
onset to use set quality standards and record particular
variables in a common way so that, upon their own study
completion, they can supply their IPD to those develop-
ing/validating a risk prediction model. Heterogeneity can
then be limited by researchers agreeing, before data col-
lection, to standardize predictor definitions, measurement
methods, and outcome recoding.
Our review has only considered articles that developed
or validated a prediction model. For risk prediction models
to become more common in practice, research also needs
to show they have a positive impact on health outcomes.
Such impact studies are currently rare [3], but they should
follow any IPD meta-analysis that develops and validates
an accurate risk prediction model.
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